Incident Report
Subform I: General Information
1. Report Type.
New incident report
Incident Report Number: 2024-6480
2. Registrant Information.
Registrant Reference Number: 3954910
Registrant Name (Full Legal Name no abbreviations): Bayer CropScience Inc.
Address: 160 Quarry Park Boulevard SE Suite 130
City: CALGARY
Prov / State: AB
Country: Canada
Postal Code: T2C 3G3
3. Select the appropriate subform(s) for the incident.
Human
4. Date registrant was first informed of the incident.
09-JUL-24
5. Location of incident.
Country: CANADA
Prov / State: SASKATCHEWAN
6. Date incident was first observed.
09-JUL-24
Product Description
7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.
Active(s)
PMRA Registration No. 30511
PMRA Submission No.
EPA Registration No.
Product Name: PROLINE GOLD SC 400
- Active Ingredient(s)
- FLUOPYRAM
- PROTHIOCONAZOLE
7. b) Type of formulation.
Application Information
8. Product was applied?
Yes
9. Application Rate.
Unknown
10. Site pesticide was applied to (select all that apply).
Site: Res. - Out Home / Rés - à l'ext.maison
11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).
Please refer to field 13 on Subform II or field 17 of subform III for a detailed description regarding application.
To be determined by Registrant
12. In your opinion, was the product used according to the label instructions?
Unknown
Subform II: Human Incident Report (A separate form for each person affected)
1. Source of Report.
Data Subject
2. Demographic information of data subject
Sex: Male
Age: >19 <=64 yrs / >19 <=64 ans
3. List all symptoms, using the selections below.
System
- Eye
- Symptom - Discharge eye
- Symptom - Irritated eye
- Gastrointestinal System
- Symptom - Irritated throat
- Symptom - Nausea
- Eye
- Symptom - Other
- Specify - Sticky
4. How long did the symptoms last?
Unknown / Inconnu
5. Was medical treatment provided? Provide details in question 13.
No
6. a) Was the person hospitalized?
No
6. b) For how long?
7. Exposure scenario
Non-occupational
8. How did exposure occur? (Select all that apply)
What was the activity? Please refer to field 13 on Subform II or field 17 of subform III for a detailed description regarding the activity
Drift from the application site
9. If the exposure occured during application or re-entry, what protective clothing was worn? (select all that apply)
None
10. Route(s) of exposure.
Respiratory
11. What was the length of exposure?
Unknown / Inconnu
12. Time between exposure and onset of symptoms.
Unknown / Inconnu
13. Provide any additional details about the incident (eg. description of the frequency and severity of the symptoms, type of medical treatment, results from medical tests, outcome of the incident, amount of pesticide exposed to, etc.)
7/9/2024 All of the following was spontaneously reported by the caller. Calling to report possible inhalation. Caller stated he was outside working at a neighbor's house. A plane flew west of them and was spraying the product. Caller thinks the wind may of blew product toward his direction. Caller stated he could smell the product and his eye became sticky and irritated and his throat is dry, as well has he is having some nausea. Caller has been drinking water. Caller stated he took a quick shower and rinsed his eyes. Issues continue. This occurred today 07/09/2024, 2 hours ago. Caller stated there was also horses outside as well.
To be determined by Registrant
14. Severity classification.
Minor
15. Provide supplemental information here.
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.